Assembly Biosciences vs SIGA Technologies
ASMB and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASMB and SIGA compare
Assembly Biosciences is the larger company, worth 2.2 times as much as SIGA Technologies ($430M against $197M).
Assembly Biosciences grew revenue faster over the last twelve months (80.2% versus −69.6% for SIGA Technologies).
SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of 1.3% compared with −16.6% at Assembly Biosciences.
SIGA Technologies pays a dividend yielding 21.9%; Assembly Biosciences does not pay one.
SIGA Technologies scores higher on the StockData Score (14 against 12 for Assembly Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASMB | SIGA |
|---|---|---|
| Size and price | ||
| Market cap | $430M | $197M |
| Share price | $21.12 | $2.74 |
| Change, 1 year | −41.1% | −55.9% |
| Change, 5 years | −23.5% | −70.4% |
| Beta (5Y) | 1.17 | 1.08 |
| Employees | 73 | 49 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 6 | 6 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 6.4× | 3.8× (better) |
| P/B | 1.4× | 1.2× (better) |
| FCF yield | −9.5% | – |
| Fair value | $22.88 | $6.01 |
| Margin of safety | 7.7% | 54.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 80.2% (better) | −69.6% |
| Revenue growth, 5Y average | −1.8% (better) | −5.4% |
| Net income growth (TTM) | – | −99.1% |
| EPS growth (TTM) | – | −100% |
| EPS growth, 5Y average | – | −14.7% |
| Profitability | ||
| Gross margin | – | 54.0% |
| Operating margin | −31.8% | −14.2% (better) |
| Net margin | −16.6% | 1.3% (better) |
| FCF margin | −60.7% | – |
| Return on equity | −4.6% | 0.37% (better) |
| Return on invested capital | – | −15.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.89 | 24.57 (better) |
| Altman Z-score | 7.10 | 13.18 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 21.9% |
| Payout ratio | – | 6325% |
| Years of dividend growth | – | 0 |
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 21.9% (better) |
| Ownership | ||
| Held by institutions | 92.1% | 48.5% |
| Held by insiders | 29.3% | 1.9% |
| Insider net buying, 12 months | −$252K | – |
| Short interest, % of float | 21.1% | 5.1% |
Go deeper
- ASMB stock overview
- ASMB income statement
- ASMB valuation and score
- SIGA stock overview
- SIGA income statement
- SIGA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.